Rheumatoid arthritis disease severity indices in administrative databases: A systematic review

Journal of Rheumatology

Volumn 38, Issue 11, 2011, Pages 2318-2325

  Vinet, Évelyne ^b   Kuriya, Bindee ^a   Widdifield, Jessica ^a   Bernatsky, Sasha ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Database management system; Insurance claim reporting; Pharmacoepidemiology; Rheumatoid arthritis; Severity of illness index

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR;

CLINICAL ASSESSMENT TOOL; CONVERGENT VALIDITY; DATA BASE; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE MARKER; DISEASE SEVERITY; FELTY SYNDROME; HUMAN; MEDICAL RECORD; MEDICAL RESEARCH; PATIENT ACTIVITY SCALE; PREDICTION; PRIORITY JOURNAL; RATING SCALE; REHABILITATION CARE; RELIABILITY; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; VALIDITY;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; DATABASE MANAGEMENT SYSTEMS; FEMALE; HEALTH SERVICES ADMINISTRATION; HUMANS; INSURANCE CLAIM REPORTING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 80155126099     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110587     Document Type: Review

References (38)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903.
2. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004;33:221-7. (Pubitemid 39180164)
3. Myasoedova E, Davis JM 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010;12:379-85.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-93.
5. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11. (Pubitemid 23068804)
6. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
7. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009;60:1884-94.
8. Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a meta-analysis of tumor necrosis factor antagonists. J Rheumatol 2010;37:928-31.
9. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70. (Pubitemid 36118917)
10. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
11. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008;168:378-81. (Pubitemid 351347129)
12. Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703. (Pubitemid 40559295)
13. Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, et al. Rheumatoid arthritis, treatment with corticosteroids, and risk of malignant lymphomas - results from a case-control study. Ann Rheum Dis 2010;69:654-9.
14. Landewe R, van der Heijde D. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther 2006;8:107.
15. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904. (Pubitemid 47502735)
16. Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res 2010;62:805-10.
17. Walker AM. Confounding by indication. Epidemiology 1996;7:335-6.
18. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
19. Landewé RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003;48:1-5. (Pubitemid 36091641)
20. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects - advantages and disadvantages. Nat Clin Pract Rheumatol 2007;3:725-32. (Pubitemid 350187018)
21. Roos LL Jr, Nicol JP, Cageorge SM. Using administrative data for longitudinal research: Comparisons with primary data collection. J Chron Dis 1987;40:41-9. (Pubitemid 17210446)
22. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64. (Pubitemid 44497754)
23. Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, et al. Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol 2005;32:1679-87. (Pubitemid 41324803)
24. Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: A preliminary study. Arthritis Res Ther 2008;10:R95.
25. Consolidated Standards of Reporting Trials. [Internet. Accessed July 22, 2011.] Available from: www.consort-statement.org
26. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37. (Pubitemid 46768164)
27. Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, Solomon DH. Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum 2005;53:61-6. (Pubitemid 40216353)
28. Sato M, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Avorn J, et al. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther 2006;8:R57.
29. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Boston: Lippincott Williams & Wilkins; 2008.
30. Wolfe F, Michaud K, Simon T. Can severity be predicted by treatment variables in rheumatoid arthritis administrative databases? J Rheumatol 2006;33:1952-6. (Pubitemid 44571866)
31. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5. (Pubitemid 41780656)
32. Pai M, McCulloch M, Enanoria W, Colford JM Jr. Systematic reviews of diagnostic test evaluations: What's behind the scenes? ACP J Club 2004;141:A11-13.
33. Ward MM. Rheumatology visit frequency and changes in functional disability and pain in patients with rheumatoid arthritis. J Rheumatol 1997;24:35-42. (Pubitemid 27059855)
34. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93. (Pubitemid 351374409)
35. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005;14:465-76. (Pubitemid 40990742)
36. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010;19:537-54.
37. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000;29:722-9. (Pubitemid 30612241)
38. Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Instrumental variables: application and limitations. Epidemiology 2006;17:260-7.